Research has found an interesting phenomenon: in lung cancer patients under 50 years old, there is a higher proportion of lung cancer with targetable genomic changes, such as EGFR mutations, ALK or ROS1 fusions, or ERBB2 insertions. The gene discussed is EGFR; the disease is lung cancer.